The four-year research initiative will focus on algae-sourced compounds that could have the potential to reduce inflammation and inflammatory bowel disease.
This confirmation expands upon the FDA's previous No Objection Letters for Nascent's Reb A to now include all steviol glycosides extracted from the leaf.
Four nonprofit industry education organizations will freely provide hundreds of chemical fingerprints for herbal and botanical ingredients to researchers.